Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2023-08-15 Purchase | 2023-08-17 5:08 pm | Neoleukin Therapeutics Inc. | NLTX | BAKER BROS. ADVISORS LP 667 L.P. Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Baker Bros. Advisors (GP) LLC Director 10% Owner | 2,285,342 | $0.64038 | $1,463,487 | 5,617,469 (Indirect Direct) | View |
2023-08-11 Sale | 2023-08-14 4:06 pm | Neoleukin Therapeutics Inc. | NLTX | Smith Sean Michael Interim CFO, Prin Acct Off | 1,323 | $0.6184 | $818 | 21,637 (Direct) | View |
2023-04-03 Sale | 2023-04-04 8:51 pm | Neoleukin Therapeutics Inc. | NLTX | Patel Priti Former Chief Medical Officer | 3,769 | $0.6919 | $2,608 | 37,313 (Direct) | View |
2023-02-02 Sale | 2023-02-03 4:33 pm | Neoleukin Therapeutics Inc. | NLTX | Smith Sean Michael Principal Accounting Officer | 3,316 | $0.5972 | $1,980 | 28,460 (Direct) | View |
2023-02-02 Sale | 2023-02-03 4:32 pm | Neoleukin Therapeutics Inc. | NLTX | Patel Priti Chief Medical Officer | 14,380 | $0.5972 | $8,588 | 66,082 (Direct) | View |
2022-08-10 Sale | 2022-08-12 5:24 pm | Neoleukin Therapeutics Inc. | NLTX | Smith Sean Michael Principal Accounting Officer | 1,655 | $0.9914 | $1,641 | 11,776 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-06-14 Option Award | 2024-06-17 2:37 pm | N/A 2034-06-14 | Neurogene Inc. | NGNE | Woods Robert Keith Director | 7,700 | $0 | 7,700 (Direct) | View |
2024-06-14 Option Award | 2024-06-17 2:37 pm | N/A 2034-06-14 | Neurogene Inc. | NGNE | PALEKAR ROHAN Director | 7,700 | $0 | 7,700 (Direct) | View |
2024-06-14 Option Award | 2024-06-17 2:36 pm | N/A 2034-06-14 | Neurogene Inc. | NGNE | BAFFI ROBERT Director | 7,700 | $0 | 7,700 (Direct) | View |
2024-06-14 Option Award | 2024-06-17 2:36 pm | N/A 2034-06-14 | Neurogene Inc. | NGNE | Noonberg Sarah B. Director | 7,700 | $0 | 7,700 (Direct) | View |
2024-06-14 Option Award | 2024-06-17 2:35 pm | N/A 2034-06-14 | Neurogene Inc. | NGNE | Freedland Cory S. Director | 7,700 | $0 | 7,700 (Direct) | View |
2024-03-13 Option Award | 2024-03-14 8:54 pm | N/A 2034-03-13 | Neurogene Inc. | NGNE | McMinn Rachel Chief Executive Officer | 93,282 | $0 | 93,282 (Direct) | View |
2024-03-13 Option Award | 2024-03-14 8:53 pm | N/A 2034-03-13 | Neurogene Inc. | NGNE | Cvijic Christine Mikail President and CFO | 85,803 | $0 | 106,744 (Direct) | View |
2024-03-13 Option Award | 2024-03-14 8:51 pm | N/A 2034-03-13 | Neurogene Inc. | NGNE | Cobb Stuart Chief Scientific Officer | 54,841 | $0 | 54,841 (Direct) | View |
2024-01-16 Option Award | 2024-01-18 7:01 pm | N/A 2034-01-16 | Neurogene Inc. | NGNE | Woods Robert Keith Director | 15,400 | $0 | 15,400 (Direct) | View |
2024-01-16 Option Award | 2024-01-18 6:58 pm | N/A 2034-01-16 | Neurogene Inc. | NGNE | PALEKAR ROHAN Director | 15,400 | $0 | 15,400 (Direct) | View |
2024-01-16 Option Award | 2024-01-18 6:56 pm | N/A 2034-01-16 | Neurogene Inc. | NGNE | Noonberg Sarah B. Director | 15,400 | $0 | 15,400 (Direct) | View |
2024-01-16 Option Award | 2024-01-18 6:53 pm | N/A 2034-01-16 | Neurogene Inc. | NGNE | Freedland Cory S. Director | 15,400 | $0 | 15,400 (Direct) | View |
2024-01-16 Option Award | 2024-01-18 6:51 pm | N/A 2034-01-16 | Neurogene Inc. | NGNE | BAFFI ROBERT Director | 15,400 | $0 | 15,400 (Direct) | View |
2024-01-16 Option Award | 2024-01-18 6:48 pm | N/A 2034-01-16 | Neurogene Inc. | NGNE | Jordan Julie Chief Medical Officer | 75,000 | $0 | 75,000 (Direct) | View |
Ownership | 2023-12-26 6:16 pm | N/A N/A | Neurogene Inc. | NGNE | Cvijic Christine Mikail President and CFO | 0 | $0 | 126,750 (Direct) | View |
Ownership | 2023-12-26 6:12 pm | N/A N/A | Neurogene Inc. | NGNE | McMinn Rachel Chief Executive Officer | 0 | $0 | 1,314,558 (Direct) | View |
Ownership | 2023-12-26 6:10 pm | N/A 2030-10-15 | Neurogene Inc. | NGNE | BAFFI ROBERT Director | 0 | $0 | 11,642 (Direct) | View |
Ownership | 2023-12-26 6:05 pm | N/A 2030-10-15 | Neurogene Inc. | NGNE | Cobb Stuart Chief Scientific Officer | 0 | $0 | 74,226 (Direct) | View |
2023-12-18 Option Award | 2023-12-20 6:43 pm | N/A N/A | Neurogene Inc. | NGNE | BAKER BROS. ADVISORS LP 667 L.P. BAKER FELIX BAKER JULIAN Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP Former 10% Owner Director | 2,877,250 | $0 | 7,831,766 (Indirect) | View |
2023-10-05 Exercise | 2023-10-10 4:22 pm | N/A N/A | Neoleukin Therapeutics Inc. | NLTX | BAKER BROS. ADVISORS LP 667 L.P. Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Baker Bros. Advisors (GP) LLC Director 10% Owner | 592,650 | $0 | 3,363,045 (Indirect) | View |
2023-08-10 Exercise | 2023-08-14 4:06 pm | N/A N/A | Neoleukin Therapeutics Inc. | NLTX | Smith Sean Michael Interim CFO, Prin Acct Off | 5,000 | $0 | 21,637 (Direct) | View |
2023-06-08 Option Award | 2023-06-12 4:03 pm | N/A 2033-06-07 | Neoleukin Therapeutics Inc. | NLTX | BAKER BROS. ADVISORS LP 667 L.P. Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Baker Bros. Advisors (GP) LLC Director | 50,000 | $0 | 50,000 (Indirect) | View |
2023-06-08 Option Award | 2023-06-09 4:28 pm | N/A 2033-06-07 | Neoleukin Therapeutics Inc. | NLTX | SIMPSON TODD E Director | 25,000 | $0 | 25,000 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 4:27 pm | N/A 2033-06-07 | Neoleukin Therapeutics Inc. | NLTX | PALEKAR ROHAN Director | 25,000 | $0 | 25,000 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 4:26 pm | N/A 2033-06-07 | Neoleukin Therapeutics Inc. | NLTX | Noonberg Sarah B. Director | 25,000 | $0 | 25,000 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 4:25 pm | N/A 2033-06-07 | Neoleukin Therapeutics Inc. | NLTX | Lavelle Erin Director | 25,000 | $0 | 25,000 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 4:24 pm | N/A 2033-06-07 | Neoleukin Therapeutics Inc. | NLTX | Babler Martin Director | 25,000 | $0 | 25,000 (Direct) | View |
2023-03-31 Exercise | 2023-04-04 8:51 pm | N/A N/A | Neoleukin Therapeutics Inc. | NLTX | Patel Priti Former Chief Medical Officer | 10,000 | $0 | 37,313 (Direct) | View |
2023-02-01 Exercise | 2023-02-03 4:33 pm | N/A N/A | Neoleukin Therapeutics Inc. | NLTX | Smith Sean Michael Principal Accounting Officer | 12,500 | $0 | 28,460 (Direct) | View |
2023-02-01 Exercise | 2023-02-03 4:32 pm | N/A N/A | Neoleukin Therapeutics Inc. | NLTX | Patel Priti Chief Medical Officer | 35,000 | $0 | 66,082 (Direct) | View |
2022-08-10 Exercise | 2022-08-12 5:24 pm | N/A N/A | Neoleukin Therapeutics Inc. | NLTX | Smith Sean Michael Principal Accounting Officer | 5,000 | $0 | 11,776 (Direct) | View |
2022-08-02 Option Award | 2022-08-04 4:43 pm | N/A 2032-08-01 | Neoleukin Therapeutics Inc. | NLTX | Walkey Carl Senior Vice President | 150,000 | $0 | 150,000 (Direct) | View |
2022-08-02 Option Award | 2022-08-04 4:41 pm | N/A 2032-08-01 | Neoleukin Therapeutics Inc. | NLTX | Smith Sean Michael Principal Accounting Officer | 150,000 | $0 | 150,000 (Direct) | View |
2022-08-02 Option Award | 2022-08-04 4:40 pm | N/A 2032-08-01 | Neoleukin Therapeutics Inc. | NLTX | Patel Priti Chief Medical Officer | 250,000 | $0 | 250,000 (Direct) | View |
2022-08-02 Option Award | 2022-08-04 4:38 pm | N/A 2032-08-01 | Neoleukin Therapeutics Inc. | NLTX | DRACHMAN JONATHAN G President and CEO | 350,000 | $0 | 350,000 (Direct) | View |
2022-08-02 Option Award | 2022-08-04 4:37 pm | N/A 2032-08-01 | Neoleukin Therapeutics Inc. | NLTX | Cochener Donna General Counsel, SVP Legal | 100,000 | $0 | 100,000 (Direct) | View |